The efficacy and safety of Orelabrutinib combined with standard chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma with high risk of CNS involvement:a prospective, single-arm clinical trial (ChiCTR) - Oct 16, 2026 - P=N/A | N=33 | Recruiting | Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
New trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|